Aprea director granted RSUs and stock options
Aprea Therapeutics director Richard Peters received equity-based compensation rather than trading shares on the market.
Rhea-AI Filing Summary
Aprea Therapeutics director Richard Peters received equity-based compensation rather than trading shares on the market. On June 16, 2026, he was granted 3,135 restricted stock units that will vest and be settled in common stock on June 16, 2027, subject to his continued service on the board and potential acceleration conditions.
He also received stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, which vest in full on June 16, 2027 under the same service and acceleration conditions and expire on June 16, 2036. Following these awards, he holds 6,254 common shares directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 15,690 shares
Grant/Award
2 txns
Insider
Peters Richard
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 12,555 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 3,135 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (Right to Buy) — 12,555 contracts (Direct);
Common Stock — 6,254 shares (Direct)
Footnotes (2)
- F1. These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
- F2. The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
Key Figures
RSU grant: 3,135 units
Options granted: 12,555 options
Option exercise price: $0.7293/share
+3 more
6 metrics
RSU grant
3,135 units
Restricted stock units granted June 16, 2026
Options granted
12,555 options
Stock options (right to buy) granted June 16, 2026
Option exercise price
$0.7293/share
Exercise price for 12,555 stock options
Option expiration
June 16, 2036
Expiration date of stock options grant
RSU vesting date
June 16, 2027
Vesting and settlement date for 3,135 RSUs
Shares after grant
6,254 shares
Common stock held directly following transaction
Key Terms
restricted stock units, Stock Options (Right to Buy), exercise price, vest in full, +1 more
5 terms
restricted stock units financial
"These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy)"
exercise price financial
"conversion_or_exercise_price": "0.7293""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in full financial
"The option vests in full on June 16, 2027, subject to the reporting person's continued service"
expiration date financial
"expiration_date": "2036-06-16T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Aprea Therapeutics (APRE) disclose for Richard Peters?
Aprea Therapeutics disclosed that director Richard Peters received equity awards, not an open-market trade. He was granted 3,135 restricted stock units and stock options for 12,555 shares, both tied to continued board service and vesting on June 16, 2027.
What stock options were granted to Richard Peters by Aprea Therapeutics (APRE)?
Richard Peters received stock options covering 12,555 shares of Aprea Therapeutics common stock at an exercise price of $0.7293 per share. The options vest in full on June 16, 2027 and are scheduled to expire on June 16, 2036.
When do Richard Peters’ Aprea Therapeutics (APRE) equity awards vest?
Both the 3,135 restricted stock units and the 12,555-share stock option grant are scheduled to vest on June 16, 2027. Vesting requires his continued service on Aprea Therapeutics’ board through that date, with potential acceleration under certain conditions.
Is Richard Peters’ Aprea Therapeutics (APRE) Form 4 a market purchase or sale?
The Form 4 reflects compensation-related grants, not a market purchase or sale. Richard Peters received restricted stock units and stock options from Aprea Therapeutics as awards for board service, both subject to vesting rather than immediate open-market trading activity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
